Cash and Cash Equivalents, at Carrying Value of NeuroSense Therapeutics Ltd. from 31 Dec 2022 to 30 Jun 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary: NeuroSense Therapeutics Ltd. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 31 Dec 2022 to 30 Jun 2025.
NeuroSense Therapeutics Ltd. Cash and Cash Equivalents, at Carrying Value for the quarter ending 30 Jun 2025 was $666,000, a 45% decline year-over-year.
Source SEC data: View on sec.gov

Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)

Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

NeuroSense Therapeutics Ltd. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$666,000	-$542,000	-45%	30 Jun 2025	6-K	01 Aug 2025	2025	Q2
Q4 2024	$3,378,000	+$738,000	+28%	31 Dec 2024	6-K	01 Aug 2025	2025	Q2
Q2 2024	$1,208,000			30 Jun 2024	6-K	30 Sep 2024	2024	Q2
Q4 2023	$2,640,000	-$903,000	-25%	31 Dec 2023	20-F	07 Apr 2025	2024	FY
Q4 2022	$3,543,000			31 Dec 2022	6-K	17 Jun 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.